Sorriso Pharmaceuticals
Sorriso Pharmaceuticals is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Sorriso Pharmaceuticals.
Sorriso Pharmaceuticals is a company.
Key people at Sorriso Pharmaceuticals.
Key people at Sorriso Pharmaceuticals.
Sorriso Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel orally delivered cytokine antibodies via its proprietary Vorabodies platform to treat immune-mediated inflammatory diseases, primarily targeting Crohn's disease and ulcerative colitis.[1][2][6] The company builds antibody therapies stable in the digestive tract, serving patients with chronic gastrointestinal conditions like moderate-to-severe ulcerative colitis, addressing unmet needs for convenient, non-invasive oral treatments over traditional injectables.[2][6] Its lead candidate, SOR102, a bispecific antibody, is in Phase 1b trials showing positive results, with additional programs like SOR104 in research for broader immunology indications; backed by $10-100M in funding, Sorriso demonstrates strong growth momentum through rapid trial progression and recent data presentations.[2][6]
Founded in 2020 and headquartered in San Diego, California, Sorriso Pharmaceuticals emerged to pioneer oral antibody delivery for inflammatory diseases, leveraging single-domain antibodies resilient to gastric conditions.[2] While specific founders are not detailed in available sources, the company quickly gained traction with investments from prominent backers like NEA and the Lundbeck Foundation, enabling swift advancement of its Vorabodies platform.[1][3] Pivotal early moments include dosing the first patients in SOR102's Phase 1b ulcerative colitis trial in May 2024, completing enrollment by September 2024, announcing positive results in December 2024, and presenting data at the ECCO conference in February 2025—marking accelerated clinical progress for a startup.[6]
Sorriso rides the wave of oral biologics innovation in immunology, where demand surges for patient-friendly alternatives to infusions amid rising IBD prevalence driven by aging populations and lifestyle factors.[2][6] Timing aligns with advances in antibody engineering for GI stability, capitalizing on market forces like the $20B+ inflammatory disease sector and post-pandemic emphasis on at-home therapies.[2] By validating oral antibodies, Sorriso influences the biotech ecosystem, potentially lowering treatment barriers, accelerating adoption in underserved GI markets, and inspiring platforms beyond immunology.[1][3][6]
Sorriso's validated Phase 1b SOR102 data positions it for Phase 2 trials in 2026, expanding to Crohn's and additional indications via SOR104 amid booming demand for oral IBD options.[6] Trends like AI-driven antibody design and personalized GI therapies will propel its trajectory, with partnerships likely amplifying reach. As a nimble player transforming antibody therapy, Sorriso could redefine immune-mediated disease treatment, evolving from pipeline innovator to market leader in oral biologics.[2][6]
